OrienX010
AXP000077.1 · Oncolytic virus
- Platform
- HSV-1 (ICP34.5- ICP47- ICP6-interrupted)
- Originator
- OrienGene Biotechnology
- Sponsor
- OrienGene Biotechnology
Names
| Name | Type | Source |
|---|---|---|
| OrienX010 | preferred name, code | curator, ncit |
Virus
- Role
- Oncolytic
- Family
- Orthoherpesviridae
- Virus
- herpes simplex virus 1 (NCBI Taxonomy 10298)
- Strain
- clinical isolate (Chinese Han patient)
- Replication
- conditionally replicating
- Modifications
- ICP34.5 and ICP47 deleted; ICP6 interrupted
- Transgenes
- CSF2
- Route
- intratumoral
- Source
- evidence
Cross-references
- NCI Thesaurus
- C111893
Approvals
No regulatory approval recorded.
Clinical trials (5)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT04197882 | Clinical Study to Evaluate OrienX010 in Combination With Toripalimab as Neoadjuvant Treatment in Advanced Melanoma | Unknown | Phase 1 | 2019-05-27 | 2021-05-27 | 33 | Melanoma |
| NCT04206358 | Study to Evaluate OrienX010 in Combination With JS001 in the Treatment of Stage IV (M1c) Liver Metastasis From Melanoma | Unknown | Phase 1 | 2019-05-13 | 2021-02-27 | 30 | Melanoma |
| NCT04200040 | A Clinical Study to Evaluate the Safety and Efficacy of OrienX010 in Unresectable Malignant Melanoma Patients | Unknown | Phase 2 | 2017-08-27 | 2022-12-27 | 165 | Melanoma (Skin) |
| NCT03048253 | A Phase I-c Study of Recombinant GM-CSF Herpes Simplex Virus to TreatⅣ M1c | Unknown | 2016-03-29 | 2017-10-10 | 30 | Melanoma | |
| NCT01935453 | A Phase I Study of Recombinant hGM-CSF Herpes Simplex Virus to Treat Cancer | Completed | Phase 1 | 2012-05 | 2014-05 | 18 | Liver Cancer; Lung Cancer; Melanoma; Pancreatic Cancer |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 42226303 | Long-term survival benefit of neoadjuvant oncolytic virus plus PD-1 blockade in acral melanoma: implications of STING in resistance and potential therapy. | Experimental hematology & oncology | 2026 | cited by trial NCT04197882 |
| PMID 39572525 | Neoadjuvant oncolytic virus orienx010 and toripalimab in resectable acral melanoma: a phase Ib trial. | Signal transduction and targeted therapy | 2024 | cited by trial NCT04197882 |
| PMID 35383116 | OrienX010, an oncolytic virus, in patients with unresectable stage IIIC-IV melanoma: a phase Ib study. | Journal for immunotherapy of cancer | 2022 | name in title: OrienX010 |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 34277838 | Current status of intralesional agents in treatment of malignant melanoma. | Annals of translational medicine | 2021 | name in abstract: OrienX010 |
| PMID 29284308 | Fighting Cancer with Viruses: Oncolytic Virus Therapy in China. | Human gene therapy | 2018 | name in abstract: OrienX010 |
| PMID 28507788 | Adaptive T cell responses induced by oncolytic Herpes Simplex Virus-granulocyte macrophage-colony-stimulating factor therapy expanded by dendritic cell and cytokine-induced killer cell adoptive therapy. | Oncoimmunology | 2017 | name in abstract: OrienX010 |
Notes
Chinese oncolytic HSV-1 armed with GM-CSF, built on a clinical isolate from a Han Chinese patient. Phase Ib in unresectable stage IIIC-IV melanoma published in J Immunother Cancer 2022.
How to cite
OrienX010 (AXP000077.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000077.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.